# A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

> **NCT03481920** · EARLY_PHASE1 · TERMINATED · sponsor: **PH Research, S.L.** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** PEGylated Recombinant Human Hyaluronidase (PEGPH20)
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03481920
- **Lead sponsor:** PH Research, S.L.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-10
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-06-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Stopped Enrollment
- **Last updated:** 2019-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03481920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03481920, "A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03481920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*